CBD Clinical Trials

Groundbreaking Safety, Toxicity, and Pharmacokinetics Study Published

ABSC Sponsored Safety Study Published in the  Journal of the American Holistic Veterinary Medical Association

We are thrilled to announce that our Phase 1 Clinical Trial: Assessment of Safety, Toxicity, and Pharmacokinetics of Cannabidiol in Healthy Dogs has been successfully completed. Sponsored by ABSC Organics and conducted at Colorado State University’s College of Veterinary Medicine and Biomedical Sciences, the trial studied three different delivery mechanisms in 30 healthy beagles. With results appearing in the Fall 2018 issue of the Journal of the American Holistic Veterinary Medical Association, the study concluded that clinical doses of CBD were well tolerated by all the dogs in the study. This is groundbreaking news in the veterinary field, and represents a major step forward for CBD research and pet wellness.

St. Bernard in CBD Clinical Trial
Dr. Stephanie McGrath with Atticus, a 3-year-old Saint Bernard enrolled in a clinical trial of cannabidiol at Colorado State University’s Veterinary Teaching Hospital (Photo by John Eisele/Colorado State University Photography)

ABSC Organics–The Only Veterinary CBD Company With a Phase 1 Safety Trial

At ABSC we know that it’s easy to make claims, but more important to invest in the research to back up those claims. We care deeply about pets and their well-being. That’s why we’re so proud of the fact that ABSC Pure Organic CBD Oil is the only veterinary CBD product that has undergone a Phase 1 trial to assess safety and toxicity. This trial enables researchers to use our product in Phase 2 trials that will study CBD’s effects on epilepsy, arthritis, and more.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *